- A Comparison of Two Ways to Manage Anti-HIV Treatment (The SMART Study)
- Corporate Support
- AIDS | SpringerLink
- In the conext of the residence of Circus Zonder Handen at Bozar
- A Comparison of Two Ways to Manage Anti-HIV Treatment (The SMART Study)
Generally, limitations of this study are considered as small due to the large sample size, the constant cooperation of the centers over the years and the near-complete covering of a defined geographic area of Germany. Thus, results are representative for the population in question and valid in the context of the study aims. In this large prospective study, we showed a moderate decline of prevalence of mutant virus strains in recent years.
Further surveillance of primary resistance is mandatory.
A Comparison of Two Ways to Manage Anti-HIV Treatment (The SMART Study)
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication.
However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor s.
The publisher and the editor s disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Privacy Policy Terms of Use Imprint. Manage with MyKarger your orders simply and fast, save your favorite articles in your reading list, edit your newsletter profile and benefit from attractive discounts.
Your password must comply with the following rules: One number One special character e. We found an already existing MyKarger account with this e-mail address:. Your MyKarger account has been created.
Corporate Support
Please check your e-mails to validate your e-mail address. To reset your password, enter your e-mail address or your user ID you registered with. You will be sent an e-mail containing a link to reset your password. A link to reset your password has been sent to your e-mail address. Follow the instructions and try to log in again.
Download Fulltext PDF. Free Access. PD Dr. Related Articles for " ".
Intervirology ;— Karger AG, Basel Introduction After more than a decade of widespread application of resistance testing in guiding highly active antiretroviral therapy HAART , it has been shown that this technique is very likely to reduce mortality in HIV-infected patients [ 1 ]. Related Articles:. Ann Intern Med ;— First-Page Preview. Oette and S. Reuter contributed equally to this paper. Karger AG, Basel. Company People Career Newsroom Contact. Sign up for MyKarger.
E-mail address.
AIDS | SpringerLink
Set Your Password. Show password Password. Log in to MyKarger? Keep me logged in. Login Forgot password. However, many asymptomatic patients are not at immediate risk of serious opportunistic diseases, the effectiveness of ART wanes over time due to HIV drug resistance, and there are short- and long-term toxicities of treatment. This motivates a comparison of two strategies: one which conserves treatments by deferring their use while the risk of opportunistic disease is low and one which aims for sustained virologic suppression, irrespective of disease risk.
In this large, long-term trial, patients will be randomly assigned to either the drug conservation DC or viral suppression VS group. Patients will be enrolled over a 3-year period and followed for an average of 7.
In the conext of the residence of Circus Zonder Handen at Bozar
Patients will be seen Months 1, 2, 4, 6, 8, 10, and 12, then every 4 months for data collection visits. All available ARTs, including immunomodulators, and resistance testing may be used by patients in both treatment groups. Selected subsamples of patients enrolled in the study will be followed with more intensive data collection for secondary outcomes relating to cost and health care utilization, quality of life, HIV transmission risk behaviors, and metabolic complications of treatment.
Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. Hide glossary Glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Search for terms x. COVID is an emerging, rapidly evolving situation.
Save this study. Warning You have reached the maximum number of saved studies Listing a study does not mean it has been evaluated by the U. Federal Government. Read our disclaimer for details. Last Update Posted : November 25, Study Description. The purpose of this study is to compare two ways of using anti-HIV drugs to help health care providers and patients decide how to best use anti-HIV treatments over many years.
Many health care providers now treat patients with daily drugs to keep the viral load as low as possible. But it is not known if this is the best way to treat patients with higher CD4 counts.
A Comparison of Two Ways to Manage Anti-HIV Treatment (The SMART Study)
Because this study will be carried out over several years, it will provide information on the long-term advantages and disadvantages of these two treatment strategies. Detailed Description:.
FDA Resources. Outcome Measures. Eligibility Criteria. Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Pregnant or breast-feeding. Contacts and Locations.
Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Publication date Collection: Caterina Novella Hospital, Galatina, Italy. Annunziata Hospital, Florence, Italy. World Health Organization, Geneva, Switzerland. Fernandez Hospital, Buenos Aires, Argentina. Gallen, St. Gallen, Switzerland. Kreckel, Berlin, Germany. Knechten, Aachen, Germany. Morgagni — L. Anna Hospital, Ferrara, Italy.